Hans M. Westgeest

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations

Christian Menzer, Alexander M. Menzies, Matteo S. Carlino et al. · Journal of Clinical Oncology · 2019 · 122 citations · Full text

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Karlijn de Joode, Daphne W. Dumoulin, Jolien Tol et al. · European Journal of Cancer · 2020 · 77 citations · Full text

Epidemiology, Cancer Epidemiology, Medicine +10

Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry

Hans M. Westgeest, Carin A. Uyl‐de Groot, R. Jeroen A. van Moorselaar et al. · European Urology Focus · 2016 · 53 citations · Full text

Urology, Cancer Screening, Medicine +7

Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences

Saskia de Groot, Naomi van der Linden, M Franken et al. · Value in Health · 2016 · 45 citations · Full text

Nursing, Primary Care, Clinical Decision Support System +14